Back To Work

Today is my first day back to work since I left to begin a clinical trial at MD Anderson on January 16th. To summarize the past three and a half months, I experienced an increase in toxicity during the first trial for a t315i leukemia mutation, fought through muscle weakness and nausea, lost some of my vision, began blogging for MD Anderson, and was accepted as a compassionate care patient for a promising drug called Ponatinib. It wasn’t quite the kind of vacation I wanted, but I may look back on this period and say it was the best thing to ever happened to me.

Continue reading “Back To Work”